Based on this assumption, GFAP and CHI3L1 as markers of astrocytic and microglial activation showed higher levels in the CSF and serum of PMS patients compared to RRMS patients (11, 12, 18, 27, 29, 36–38). This evidence concerns the gene GFAP and premenstrual tension.